醋酸乌利司他中间体 T6713

Product Introduction
Bioactivity


英文名: Ulipristal

描述: Ulipristal 是性孕酮受体 (progesterone receptor) 的选择性调节剂。它能够与孕激素受体结合，抑制 PR 介导的基因表达，降低生殖系统中孕激素的活性。

体外活性: Ulipristal acetate 对孕酮受体具有部分激动与拮抗效应。它还能结合到糖皮质激素受体，但对雌激素、雄激素和矿物皮质激素受体无显著亲和力。[1]

体内活性: Based on clinical trials, ulipristal acetate seems to be a reasonably tolerable and effective method of emergency contraception when used within 120 hours of intercourse. Ulipristal acetate is at least as effective as LNG when used within the first 72 hours after unprotected intercourse. However, ulipristal acetate may be more effective than LNG when used between 72 to 120 hours after unprotected intercourse, extending the window of opportunity for emergency contraception. [2][3]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 77 mg/mL (177.6 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 12 mg/mL (27.7 mM)


关键字: emergency | Deacetyl CDB2914 | inhibit | contraception | CDB 3236 | Progesterone Receptor | CDB3236 | Deacetyl CDB 2914 | NR3C3 | leiomyoma | anti-progestational | Inhibitor | CDB-3236 | Ulipristal | uterine | Deacetyl CDB-2914 | anti-glucocorticoid | anti-fertility

相关产品: Nestoron | Mifepristone | Elacestrant | Psoralidin | Bavachin | Giredestrant | Estradiol | Allura Red AC | Hinokitiol | Medroxyprogesterone Acetate

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | ReFRAME Related Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library | Bioactive Compound Library

醋酸乌利司他中间体 T6713信息由TargetMol中国为您提供，如您想了解更多关于醋酸乌利司他中间体 T6713报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途